Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

AZ is now planning to move ahead with a phase 2 programme for its drug, although there’s no doubt it is playing catch-up in the oral PCSK9 inhibitor category with MSD – known as Merck & Co in ...

Merck & Co has said building its cardiovascular ... “[This data reinforces] our confidence that MK-0616 could become the first oral PCSK9 inhibitor, with the potential to change the way patients ...

Thank you for standing by. Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded. [Operator instructions] I would now like to ...

Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...

Merck achieved revenue growth in Q4, but stocks tumbled Tuesday amid news that the company is pausing Gardasil shipments to China. © 2024 Fortune Media IP Limited ...

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company expects adjusted earnings per share for the year to range from $8.88 to ...

The pause announcement comes a month after Merck received approval in China for use of the vaccine in males. “We believe China still represents a significant, long-term opportunity for Gardasil ...

M.R.W. is on the speaker’s bureau for Merck and has acted as a consultant for Merck. L.L. has acted as a consultant for Merck, Novartis, and Bayer, and has received grants from Pfizer ...